HCAL
ARQT icon

HURRICANE CAPITAL ADVISORS LLC’s Arcutis Biotherapeutics ARQT Stock Holding History

HURRICANE CAPITAL ADVISORS LLC’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$168K Sell
6,414
-2,565
-29% -$59.8K 0.04% 413
2026
Q1 		$212K Buy
8,979
+4,870
+119% +$124K 0.07% 264
2025
Q4 		$119K Sell
4,109
-3,147
-43% -$80.6K 0.04% 375
2025
Q3 		$137K Sell
7,256
-14,007
-66% -$221K 0.03% 382
2025
Q2 		$298K Buy
21,263
+10,593
+99% +$148K 0.07% 189
2025
Q1 		$167K Buy
+10,670
New +$150K 0.06% 225
2024
Q3 		– Sell
-12,500
Closed -$116K – 556
2024
Q2 		$116K Buy
+12,500
New +$113K 0.04% 281

Other funds holding ARQT

Suvretta Capital Management
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HURRICANE CAPITAL ADVISORS LLC's ARQT Position: Q2 2026 in Review

HURRICANE CAPITAL ADVISORS LLC reduced its Arcutis Biotherapeutics (ARQT) stake by 29% in Q2 2026, selling an estimated $59.8K and leaving 6,414 shares worth $168K. The position accounts for 0.04% of the portfolio, ranked #413.

HURRICANE CAPITAL ADVISORS LLC first reported a position in ARQT in Q2 2024 and has held it in 7 quarters since. The position peaked at $298K in Q2 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • HURRICANE CAPITAL ADVISORS LLC held 6,414 shares of Arcutis Biotherapeutics worth $168K as of Q2 2026.
  • HURRICANE CAPITAL ADVISORS LLC sold 2,565 Arcutis Biotherapeutics shares in Q2 2026, an estimated $59.8K.
  • Arcutis Biotherapeutics made up 0.04% of HURRICANE CAPITAL ADVISORS LLC's portfolio in Q2 2026, its #413 holding.
  • HURRICANE CAPITAL ADVISORS LLC first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 7 quarters since.
  • HURRICANE CAPITAL ADVISORS LLC's Arcutis Biotherapeutics position peaked at $298K in Q2 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on HURRICANE CAPITAL ADVISORS LLC's 13F filing for Q2 2026, filed 3 Nov 2026.